Introduction: In a preceding trial comparing
INTRODUCTION
Insulin degludec/insulin aspart (IDegAsp) is the first soluble co-formulation of two separate insulins, containing 70% insulin degludec (IDeg) and 30% insulin aspart (IAsp) in a single injection, retaining the properties of the original formulations [1] . IDeg forms soluble multi-hexamers at the injection site and is slowly absorbed, while IAsp hexamers dissociate upon injection into rapidly absorbed monomers.
This results in a novel pharmacokinetic and pharmacodynamic profile compared with premix insulins, characterized by the distinct basal to prandial effect observed with IDegAsp [2] , with a stable basal insulin coverage over a 24-h period due to the IDeg component, and without the need for resuspension. IDegAsp is recommended to be administered once (OD) or twice daily (BID) with main meal(s) [3] .
Two clinical trials in the IDegAsp clinical development program showed that, compared with biphasic insulin aspart 30 (BIAsp 30), treatment intensification with IDegAsp BID over 26 weeks results in fewer confirmed, nocturnal confirmed, and severe hypoglycemic episodes whilst reaching the non-inferiority margin for mean reduction in HbA 1c [4, 5] . A combined analysis of these two trials reports that estimated rate ratios of overall confirmed, nocturnal confirmed, and severe hypoglycemic respectively [6] .
A preceding trial to the current one added further understanding of two different titration algorithms (e.g., a ''simple'' algorithm using twice-weekly dosing adjustments and a ''stepwise'' algorithm using once-weekly dose adjustment) of the new co-formulation of IDegAsp BID, when used as an intensification regimen in patients inadequately controlled with a basal-only regimen (i.e., insulin glargine OD) [7] . After 26 weeks of IDegAsp BID treatment, 67% of patients successfully achieved the recommended HbA 1c target of less than 7%, accompanied by significant reductions in fasting plasma glucose (FPG), while rates of hypoglycemia were in line with previous trials of intensification with IDegAsp BID [4] [5] [6] [7] [8] .
At the end of the preceding trial, a small sample of patients were left still experiencing poor glycemic control (HbA 1c C7.0%) [7] . These represent a group of difficult-to-treat patients 
METHODS

Sample
The sample was recruited from 68 male and female patients (C18 years with a body mass
) who had failed to achieve glycemic control following 26 weeks of treatment with IDegAsp BID [7] .
Key exclusion criteria were the presence of cardiovascular (CV) events (e.g., stroke) between the start of the preceding trial and consenting to the present trial, uncontrolled hypertension (i.e., systolic blood pressure C180 mmHg and/or diastolic blood pressure C100 mmHg) and the presence of recurrent severe hypoglycemia (more than one event within the previous 12 months), or hypoglycemic unawareness, as evaluated by the investigator. Dipeptidyl peptidase 4 inhibitors (DPP-4) and/or metformin was allowed only if continued from the preceding trial; commencement of new oral antidiabetic agents (OADs) during the trial was prohibited.
Of the 68 patients eligible for screening, 47 consented to enter into the current trial, of which seven failed screening (six patients failed because their HbA 1c was less than 7% and one patient failed because of impaired renal function). Forty patients were randomized and 10 patients withdrew during the trial, which resulted in 30 completers (15 completers in each treatment group). The proportion of subjects withdrawn from the trial was the same between the two treatment groups. One subject (in the IDeg OD ? IAsp TID group) was withdrawn because of an adverse event (AE). There was no apparent pattern in the withdrawals and no apparent clustering of withdrawals at any specific time point during the trial.
Design
This was a 26-week, randomized, open-label, phase 3b, treat-to-target, exploratory trial in which patients were randomized 1:1 to either IDegAsp BID ? IAsp OD ± OADs or IDeg OD ? IAsp TID ± OADs. Participating countries were the USA (n = 26), Malaysia (n = 11), Germany (n = 2), and Turkey (n = 1).
Compliance with Ethics Guidelines
All procedures followed were in accordance with the ethical standards of the responsible Informed consent was obtained from all patients for being included in the trial.
Trial Endpoints
The primary endpoint was change from baseline in HbA 1c after 26 weeks. The secondary endpoints were FPG, mean 8-point self-measured plasma glucose (SMPG), post-prandial glucose (PPG) increment, insulin dose, and body weight.
Safety endpoints included the total number of AEs in each treatment group, the number of serious adverse events (SAEs), the AE rate per 100 patient-years of exposure (PYE), and the number of patients withdrawn due to AEs.
Confirmed hypoglycemic episodes included episodes with a measured plasma glucose (PG) value of less than 3.1 mmol/L or severe episodes (severe defined as requiring assistance from another person to treat). Confirmed hypoglycemic events that occurred during 0001-0559 hours (both inclusive) were classified as nocturnal.
Insulin Dose and Titration
In the IDegAsp BID ? IAsp OD treatment arm, IDegAsp was administered with breakfast and the evening meal and IAsp was administered with lunch. Patients restarted their end of trial (EOT) IDegAsp BID dose used in the preceding trial [7] and the lunchtime IAsp starting dose was 4 units (U).
In the IDeg OD ? IAsp TID treatment arm, IDeg was administered at any time of the day.
IAsp was administered with breakfast, lunch, and the evening meal. The starting IDeg dose was 70% of the EOT total daily dose from the preceding trial [7] . The starting IAsp dose was 30% of the total EOT dose from the preceding trial divided into three doses per day.
IDeg and IDegAsp were titrated as per the stepwise algorithm in the preceding trial [7] .
IDegAsp was dosed according to weekly adjustments based on the lowest of 3 days' pre-breakfast and pre-evening meal SMPG measurements. IDeg was dosed according to the lowest of three consecutive days' pre-breakfast SMPG measurements prior to titration. IAsp was dosed according to the lowest of three consecutive days' SMPG measurements at the following timepoints: 
RESULTS
The baseline characteristics of the patients are presented in Table 1 Supplementary Table S1 . ranging from 48.2% to 56.5% [4] [5] [6] 8] . In the preceding titration trial comparing a simple vs. stepwise titration of IDegAsp BID in patients previously inadequately controlled on basal insulin, the overall responder rate for intensification with IDegAsp BID was 67% [7] , which is higher than that seen in the earlier studies [4] [5] [6] 8] .
Nevertheless, there was a small population of more difficult-to-treat patients, for whom poor glycemic control persisted despite insulin intensification beyond basal-only treatment [7] . This scenario is clinically interesting and is commonly encountered in real-world clinical practice. Therefore, the current trial provides relevant treatment information for clinicians regarding the efficacy and safety of further insulin intensification using two different strategies. However, as a result of the low number of patients participating in this exploratory trial, the results should be confirmed by further clinical trials.
Adding observed, and the mean increase in body weight was similar for both treatment arms.
The frequency of AEs observed during treatment was similar in both treatments and in line with existing trials, with few severe hypoglycemic episodes being reported and no new safety issues being identified [4] [5] [6] [7] [8] .
As recommended in the most recent American Diabetes Association (ADA)
guidelines, treatment for T2D should be personalized, culturally appropriate, and take into account the patient's own preferences and expectations [9] . As demonstrated in the current trial, treatment adaptations may be challenging 
